COVID-19 Herbs: Ginkgo Biloba And Rhodiola Rosea For Post-COVID Cognitive Impairment And Fatigue

COVID-19 Herbs: The COVID-19 pandemic has left a lasting impact on global health, with millions of individuals experiencing prolonged symptoms even after recovering from the acute phase of the infection. Among these lingering symptoms, cognitive impairment and fatigue have emerged as significant challenges for many individuals diagnosed with post-COVID syndrome (PCS). While traditional pharmaceutical interventions have been largely ineffective in addressing the multifaceted nature of PCS, herbal remedies offer a promising alternative. In particular, Ginkgo biloba and Rhodiola rosea, with their multi-target pharmacological properties, have garnered attention for their potential to alleviate cognitive impairment and fatigue in individuals recovering from COVID-19. This COVID-19 Herbs news report focuses on a study review by German researchers from the University Hospital Frankfurt and Goethe University Frankfurt on the potential of of using Ginkgo biloba and Rhodiola rosea for post-COVID cognitive impairment and fatigue.

 Gingko Biloba

Understanding Post-COVID Syndrome
Post-COVID syndrome (PCS) refers to a constellation of persistent symptoms that persist beyond the acute phase of COVID-19 infection. While the severity of the initial illness does not necessarily correlate with the development of PCS, neuropsychiatric symptoms, including cognitive deficits and fatigue, are common among affected individuals. These symptoms, often accompanied by somatic manifestations, significantly impact the quality of life and functional capacity of PCS patients, highlighting the need for effective therapeutic interventions.
 
The Complex Pathophysiology of Cognitive Impairment and Fatigue
The pathophysiology underlying cognitive impairment and fatigue in PCS is multifaceted, involving intricate interactions between oxidative stress, mitochondrial dysfunction, and neuroinflammation. Emerging evidence suggests a significant overlap between these symptoms, with chronic inflammation emerging as a common underlying factor. This complex interplay underscores the limitations of conventional pharmaceutical interventions, which often target isolated pathways and may overlook the multifactorial nature of PCS.
 
The Promise of Herbal Multitarget Drugs
In contrast to conventional pharmaceuticals, herbal remedies offer a holistic approach to addressing the complex pathophysiology of PCS. Ginkgo biloba and Rhodiola rosea, two widely studied botanicals, possess a diverse array of bioactive compounds with multi-target pharmacological properties. These herbal remedies have been traditionally used for their cognitive-enhancing, anti-inflammatory, and adaptogenic effects, making them promising candidates for alleviating cognitive impairment and fatigue in PCS patients.
 
Ginkgo Biloba: Nature's Cognitive Enhancer
Ginkgo biloba, derived from the leaves of the Ginkgo tree, has a long history of use in traditional medicine for enhancing cognitive function and improving memory. In its standardized extract form, known as EGb761, Ginkgo biloba contains a unique combination of terpenoids and flavonoids with potent antioxidant and anti-inflammatory properties. Preclinical studies have demonstrated Ginkgo biloba’s ability to enhance neuroplasticity, reduce neuroinflammation, and improve mitochondrial function, all of which are relevant to the pathophysiology of PCS-related cognitive impairment.
 
Clinical studies have also provided evidence for the cognitive-enhancing effects of Ginkgo biloba in various populations, including older adults with age-related cognitive decline and patients with neurodegenerative disorders such as Alzheimer's disease. While limited, preliminary evidence suggests that Ginkgo biloba may also offer benefits for reducing fatigue, particularly in conditions characterized by chronic inflammation such as multiple sclerosis. However, further research is needed to elucidate the specific mechanisms underlying Ginkgo biloba's effects on fatigue in the context of PCS.


Rhodiola-Rosea

Rhodiola Rosea: Nature's Adaptogen
Rhodiola rosea, commonly known as golden root or Arctic root, is a perennial herb native to the mountainous regions of Europe and Asia. As an adaptogen, Rhodiola rosea has been traditionally used to enhance resilience to stress, improve physical and mental performance, and promote overall well-being. The bioactive compounds found in Rhodiola rosea, including salidroside and rosavins, exert adaptogenic effects by modulating the body's stress response systems and enhancing cellular energy metabolism.
 
Preclinical studies have demonstrated Rhodiola rosea's neuroprotective, anti-fatigue, and antidepressant effects, which are attributed to its ability to regulate neurotransmitter levels, reduce oxidative stress, and modulate neuroinflammation. Clinical trials have also provided evidence for Rhodiola rosea's efficacy in improving cognitive function, reducing fatigue, and alleviating depressive symptoms in various populations, including patients with burnout, chronic fatigue syndrome, and stress-related disorders. While research specifically focused on Rhodiola rosea's effects in PCS is limited, its well-established adaptogenic properties make it a promising candidate for addressing cognitive impairment and fatigue in PCS patients.
 
Clinical Evidence and Future Directions
Despite the promising preclinical and clinical evidence supporting the use of Ginkgo biloba and Rhodiola rosea in PCS, further research is needed to validate their efficacy, safety, and optimal dosing regimens in this context. Well-designed clinical trials with larger sample sizes, longer follow-up periods, and rigorous outcome measures are essential to establish the therapeutic potential of these herbal remedies in PCS patients. Additionally, mechanistic studies exploring the underlying biological pathways involved in their effects on cognitive impairment and fatigue may provide valuable insights into their therapeutic mechanisms of action.
 
Conclusion
Ginkgo biloba and Rhodiola rosea represent promising botanical interventions for alleviating cognitive impairment and fatigue in individuals recovering from COVID-19. Their multi-target pharmacological properties, coupled with their historical use in traditional medicine, make them attractive candidates for inclusion in comprehensive treatment strategies for PCS. However, robust clinical evidence supporting their efficacy and safety in PCS patients is still evolving, underscoring the need for further research in this area. As our understanding of the pathophysiology of PCS continues to advance, harnessing the therapeutic potential of these natural remedies may offer new avenues for improving the quality of life and functional outcomes of individuals affected by this debilitating condition.
 
The study review was published in the peer reviewed journal of Neural Transmission.
https://link.springer.com/article/10.1007/s00702-024-02749-3
 
For the latest on COVID-19 Herbs, Keep on logging to Thailand Medical News.